Cargando…
Effect of interleukin 2 on urinary excretion of degradation products of prostacyclin and thromboxane A2 in patients with ovarian cancer.
We studied the effect of intraperitoneal recombinant interleukin 2 (rIL-2) on the production of prostacyclin (PGI2) and thromboxane A2 (TxA2) in six patients with metastatic ovarian malignancy. Time-span urine samples collected before and after 17 intraperitoneal instillations of IL-2 (6 x 10(5) IU...
Autores principales: | Aitokallio-Tallberg, A., Lehtovirta, P., Vartiainen, J., Ylikorkala, O. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1995
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2034019/ https://www.ncbi.nlm.nih.gov/pubmed/7547215 |
Ejemplares similares
-
Urinary excretion of prostacyclin and thromboxane degradation products in patients with ovarian malignancy: effect of cytostatic treatment.
por: Aitokallio-Tallberg, A., et al.
Publicado: (1989) -
Prostacyclin and thromboxane in breast cancer: relationship between steroid receptor status and medroxyprogesterone acetate.
por: Aitokallio-Tallberg, A., et al.
Publicado: (1985) -
Prostacyclin and thromboxane in benign and malignant breast tumours.
por: Laekeman, G. M., et al.
Publicado: (1986) -
Comparative effects of immediate‐release and extended‐release aspirin on basal and bradykinin‐stimulated excretion of thromboxane and prostacyclin metabolites
por: Gamboa, Jorge L., et al.
Publicado: (2016) -
Elevated Ratio of Urinary Metabolites of Thromboxane and Prostacyclin Is Associated with Adverse Cardiovascular Events in ADAPT
por: Montine, Thomas J., et al.
Publicado: (2010)